Thormann J, Kramer W, Kindler M, Neuss H, Bahawar H, Schlepper M
Z Kardiol. 1984 Dec;73(12):772-85.
According to investigations conducted in Japan, TA-064 is a new cardiotonic agent, which is also effective orally. We analyzed computer-assisted alterations of pressure-volume relations serially and of MVO2 online (Bretschneider) during TA-064 influence in 16 patients with congestive cardiomyopathy: LV-function of 7 patients was only moderately decreased (group A) and in 9 patients massively (group B).
In both groups A and B TA-064 improves LV-function primarily via increased contractility, without toxic side effects. For a more complex definition of the efficiency and mechanism of cardiotonic agents, the validity and importance of using on-line MVO2 assessment and analysis of serial pressure-volume relations is stressed.
根据在日本进行的调查,TA - 064是一种新型强心剂,口服也有效。我们连续分析了16例充血性心肌病患者在TA - 064作用期间压力 - 容积关系的计算机辅助变化以及在线(布雷tschneider)的MVO2:7例患者的左心室功能仅中度下降(A组),9例患者严重下降(B组)。
1)静脉注射TA - 064,8微克/千克/分钟,两组均有正性肌力作用,在输注约第5分钟时诱导的平均最大δ%变化如下:左心室每搏作功指数(LVSWI)分别增加65%和47%;最大dp/dt分别增加61%和59%;左心室效率分别增加62%和53%;MVO2分别增加31%和11%(p小于0.05)。2)口服TA - 064,20毫克,诱导的血清水平(A组:23.8±12和B组:26.4±20纳克/毫升)与静脉注射剂量1 - 2微克/千克/分钟的效果相当(p大于0.05),这意味着左心室功能的显著变化需要更高的口服剂量。3)在用药第6天静脉注射TA - 064产生的左心室功能改善比第1天少(p大于0.05)。
在A组和B组中,TA - 064主要通过增加收缩力改善左心室功能,无毒性副作用。为了更复杂地定义强心剂的效率和机制,强调了使用在线MVO2评估和连续压力 - 容积关系分析的有效性和重要性。